Short answer
Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). RAP-219 Phase 2a follow-up results presented at the 2026 American Academy of Neurology Annual Meeting.
Rapport Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- RAP-219 Phase 2a follow-up results presented at the 2026 American Academy of Neurology Annual Meeting
- Sustained seizure reduction supports RAP-219’s continued development for focal onset seizures
- Updated corporate presentation signals investor-facing messaging and program updates
- Full efficacy and safety details available in Exhibits 99.1 and 99.2
Item 8.01 · Other Events
- RAP-219 sustained responses after treatment, with 80% LE and 90% clinical-seizure reductions in weeks 9–12
- Responses persisted through weeks 13–16, showing 68% LE and 59% clinical-seizure reductions versus baseline
- Estimated half-life increased to approximately 22 days from 14 days, supporting less frequent dosing potential
- Weeks 1–16 showed 69% LE and 68% clinical-seizure reductions; seizure freedom reached 12%
- Follow-up tolerability remained favorable, with two mild treatment-related events and three unrelated serious events
Item EX-99.1 · Exhibit EX-99.1
- RAP-219 sustained clinical activity after dosing stopped: median seizure reduction 90% in weeks 9–12 and 59% in weeks 13–16
- Approximately 22-day half-life supports durable exposure, with 60%–75% receptor occupancy through weeks 13–16
- Generally well tolerated; two mild treatment-related adverse events and three unrelated serious adverse events during follow-up
- Phase 3 FOCUS 1 and FOCUS 2 trials expected to begin in Q2 2026, creating an important clinical catalyst
- Evidence remains early-stage: open-label Phase 2a study enrolled 30 patients, with exploratory analyses lacking multiplicity control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rapport Therapeutics, Inc. 8-K filings
Get the next RAPP 8-K as it lands
Follow RAPP for push alerts, or ask the research agent what this filing means.